Effect of tetravalent bispecific CD19×CD
✍
Uwe Reusch; Fabrice Le Gall; Manfred Hensel; Gerhard Moldenhauer; Anthony D. Ho;
📂
Article
📅
2004
🏛
John Wiley and Sons
🌐
French
⚖ 284 KB
## Abstract To develop an effective antitumor immunotherapy for B‐lineage non‐Hodgkin's lymphoma, we constructed a tetravalent tandem diabody (tanDb) specific for both human CD19 (B‐cell marker) and CD3 (T‐cell antigen). Here, we report the effective killing of malignant primary B cells from patien